Back to Blog
    AIGovernanceRisk ManagementCybersecurity

    The Quiet Risk in Pharma's AI Rush: Nobody Owns the Governance

    Ayoub Saboumazrag, Founder & Managing PartnerAugust 3, 2026
    The Quiet Risk in Pharma's AI Rush: Nobody Owns the Governance

    Everyone in pharma is talking about AI adoption. Far fewer are talking about who's accountable when an AI system gets a decision wrong.

    That's a problem, because the regulators have already started talking about it.

    The EU AI Act is now in force, and a lot of what pharma does with AI lands squarely in its higher-risk categories, anything touching patient safety, clinical decision support, or pharmacovigilance. Meanwhile ISO 42001, the first management-system standard for AI, gives organizations a framework to actually govern these systems instead of governing them in a slide deck. Two different instruments, same underlying message: deploying AI now comes with documentation, oversight, and accountability requirements you can't bolt on later.

    Scales weighing an AI brain against EU AI Act and ISO 42001 binders

    What keeps happening on the ground

    A team stands up a model to triage adverse event reports or screen literature. It works. It saves real time. And then someone in quality asks the obvious questions: Who validated this? What data did it train on? What happens when it's wrong? How do we explain it to an inspector? And the room goes quiet.

    The technology was the easy part. The governance was the part nobody assigned.

    What "good" actually looks like

    It's less dramatic than people fear:

  1. Know what you're running: Most organizations can't produce a clean inventory of where AI is being used across R&D, manufacturing, safety, and commercial. You can't govern what you can't see. Start there.
  2. Classify by risk, not by hype: A model recommending content to a sales rep and a model influencing a safety signal are not the same risk. The EU AI Act forces this distinction; your internal process should too.
  3. Make a human genuinely accountable: Not "human in the loop" as a checkbox, but a named person who understands the system, can challenge its output, and owns the outcome.
  4. Document as you build, not after: ISO 42001 rewards organizations that treat governance as part of development. Retrofitting documentation onto a system that's already live is painful, expensive, and usually incomplete.

    5. Governance as the accelerator

    The instinct in a regulated industry is to slow everything down until the rules are perfectly clear. But that's not the move here. The organizations getting this right are using governance as the thing that lets them move faster, because their legal, quality, and clinical teams trust the systems enough to actually approve them.

    Governance isn't the brake on AI in pharma. Right now, it's looking like the accelerator.

    If your team is deploying AI faster than it's governing it, that gap is worth closing before an auditor closes it for you.

    What's your organization leaning on first, ISO 42001 as a framework, or building straight to EU AI Act compliance?

    Explore related services

    AI Transformation Services Cloud Services ISO 27001 gap analysis